^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor) +
    Empliciti (elotuzumab) (CS-1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    the NCCN Panel has included elotuzumab/bortezomib/dexamethasone as a treatment option for patients with relapsed/refractory MM... Multiple Myeloma: Therapy for previously treated multiple myeloma…Other Recommended Regimens…Elotuzumab/bortezomib/dexamethasone
    Secondary therapy:
    dexamethasone